Prevalence of past and reactivated viral infections and efficacy of cyclosporine a as monotherapy or in combination in patients with psoriatic arthritis - Synergy study: A longitudinal observational study

Delia Colombo, Sergio Chimenti, Paolo Grossi, Antonio Marchesoni, Sergio Di Nuzzo, Vito Griseta, Anna Gargiulo, Aurora Parodi, Lucia Simoni, Gilberto Bellia

Research output: Contribution to journalArticle

Abstract

We have prospectively evaluated psoriatic arthritis (PsA) patients for (1) seropositivity for former viral infections and seroconversion and (2) efficacy of cyclosporine A (CsA) alone or in combination with other immunosuppressants in a time period of 12 months. Screening included HBV antibodies and antigens, HCV antibodies and RNA, HSV 1-2, HZV, EBV, and CMV IgG, and IgM, HHV-6 DNA, and HIV 1-2 antibodies. PsA was evaluated by the Psoriasis Area Severity Index (PASI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Visual Analogue Scale (VAS). At baseline, 126 (56%) out of 225 evaluable patients had 2 or more seropositivities indicative of former infections, and 31 patients (13.8%) presented seropositivity for HCV, HBV, HSV-1 and -2, HHV-6, EBV, or parvovirus infection; one of them, positive for HBAg, was treated with lamivudine, while the remaining 30 received no specific treatment. None of the 31 patients developed virus reactivation. A reduction (P

Original languageEnglish
Article number941767
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Prevalence of past and reactivated viral infections and efficacy of cyclosporine a as monotherapy or in combination in patients with psoriatic arthritis - Synergy study: A longitudinal observational study'. Together they form a unique fingerprint.

  • Cite this